Iran Diabetes Care Drugs Market is Segmented by Drugs (Oral Anti-diabetic Drugs, Insulin, Non-insulin Injectable Drugs, and Combination Drugs). The report offers the value (in USD million) for the above segments.

Iran Diabetes Care Drugs Market Size

Study Period: 2018 - 2028
CAGR: > 4 %

Major Players


*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and it's growth?

Iran Diabetes Care Drugs Market Analysis

The Iran Diabetes Care Drugs Market is expected to register a CAGR greater than 4% forecast period, 2022-2027.

Inadequate preventive measures interrupted traditional methods of relationship with the patient, medication shortages, disruption of routine diabetic care, and a lack of the necessary infrastructure for telehealth services are the most significant challenges of diabetes care management in developing countries during the COVID-19 pandemic. Diabetes is becoming more common in Iran, as it is in many other countries. In addition to the difficulties inherent in diabetes management in impoverished countries, Iran has faced new challenges in the last two years as sanctions have tightened. The weight of sanctions in Iran more than tripled during the COVID-19 crisis.

Regular blood glucose monitoring, following a healthy diet, regular physical activity, and compliance with medication and foot care are the most important components of diabetes self-management that should be considered to better control hyperglycemia and prevent or at least delay complications in diabetic patients. During the COVID-19 crisis, shortages or high pricing of devices such as insulin pens heightened patients' concern and hindered their illness management.

Insulin has a substantial market share in the pharmaceutical industry. Insulin is used by around 100 million people globally, including all patients with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin manufacturing is highly complicated, with just a few insulin producers on the market. As a result, there is tremendous competition among these companies, which are always seeking to meet patient requests by offering the highest-quality insulin.

Iran Diabetes Care Drugs Industry Segmentation

Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body's cells do not respond properly to insulin or both. The diabetes care drugs market is segmented by drugs into Insulin (Basal Or Long-Acting, Bolus Or Fast-Acting, Traditional Human Insulin Drugs, and Insulin Biosimilars), Oral Anti-Diabetic Drugs (Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists, and Amylin Analogue), and Combination Drugs (Combination Insulin, Oral Combination).

Oral Anti-diabetic drugs (Value and Volume, 2016-2027)
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Galvus (Vildagliptin)
Insulins (Value and Volume, 2016-2027)
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs (Value and Volume, 2016-2027)
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs (Value and Volume, 2016-2027)
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)

Report scope can be customized per your requirements. Click here.

Iran Diabetes Care Drugs Market Trends

This section covers the major market trends shaping the Iran Diabetes Care Drugs Market according to our research experts:

Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in 2021

The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 3.8% during the forecast period, mainly due to the demand from the diabetes population, which was more than 5.7 million by the end of 2022.

Diabetes sufferers in Iran confront financial difficulties. Pharmacies do not sell enough insulin to diabetics; instead, insulin is sold on the open market at a higher price. Sometimes a diabetic child's parent is unable to locate insulin. Insulin costs 20-30% of a family's monthly income for type 1 diabetic children and adults. This does not include the excessively high cost of test strips and other supplies. In addition, insurance firms in Iran are lowering financial assistance for diabetes treatments. Because insulin is scarce, Iranian families with diabetes children adapt by limiting the number of carbs in their child's diet. Though food and lifestyle are highly helpful in managing blood glucose levels, they frequently fail and necessitate oral medication therapy. If the second phase of pharmacological therapy fails, oral multiple therapies will be used. Multiple therapies will be optimized, and in the ultimate stages, it will be shifted to oral-injectable multiple treatments. With broad modifications in hyperglycemia prescription therapy, guidelines for regulating blood glucose levels have evolved over time. Considering these developments in diabetes care, the trend in the use of glucose-lowering medicines, as well as their efficacy to control blood glucose, is critical.

One of the most prevalent difficulties in patients is poor drug adherence. Many patients struggle to adhere to therapy suggestions. Adherence to oral hypoglycemic medications (OHAs) ranges from 36% to 93% in both type 1 and type 2 diabetes. Sulphonylureas are commonly used to treat type 2 diabetes. Patient compliance is critical to the efficacy of oral diabetes therapy. It became vital to emphasize the recent status of diabetic medication adherence among type 2 diabetes patients in Tehran, as well as the cultural variances within the same Iranian community.

Through the Iran government’s encouragement, the usage of Drugs increased over the forecast period.


The rising prevalence of diabetes in Iran is boosting the country's diabetes drugs market.

In Iran, diabetes is a leading cause of mortality, blindness, renal failure, heart attack, stroke, and amputation of lower limbs. According to estimates by the National Program for Prevention and Control of Diabetes, diabetes will affect 9.2 million Iranians by 2030. This steady and large rise in diabetes prevalence reflects Iran's high disease burden, particularly when diabetes-related comorbidities are included. In accordance with the serious worldwide attempts to lower the burden of diabetes, Iran's National Program for Prevention and Control of Diabetes (NPPCD) has achieved significant progress in providing effective diabetes prevention for the general population and long-term treatment for diabetic patients. Despite the NPPCD's ongoing efforts to provide local, regional, and subnational estimates of diabetes, the current state of type-specific status, natural history, comorbidities, quality and accessibility of care, indicators of control, diabetes-related complications, and burden of diabetes among patients with diabetes in Iran remains poorly characterized.

Thus, owing to the above factors it is expected to drive the market growth over the forecast period.


Iran Diabetes Care Drugs Industry Overview

The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

Iran Diabetes Care Drugs Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Astrazeneca

  4. Sanofi

  5. NovoNordisk

*Disclaimer: Major Players sorted in no particular order


Iran Diabetes Care Drugs Market News

  • In Feb 2022, Diabetes Drug firm Abbott said it has tied up with various health-tech firms like BeatO,, PharmEasy, GOQii, 1MG, and Zyla for diabetes care. The company said it has also joined hands with Health, HealthifyMe, and Fitterfly under the initiative.

Iran Diabetes Care Drugs Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 Oral Anti-diabetic drugs (Value and Volume, 2016-2027)

      1. 5.1.1 Biguanides

        1. Metformin

      2. 5.1.2 Alpha-Glucosidase Inhibitors

        1. Alpha-Glucosidase Inhibitors

      3. 5.1.3 Dopamine D2 receptor agonist

        1. Bromocriptin

      4. 5.1.4 SGLT-2 inhibitors

        1. Invokana (Canagliflozin)

        2. Jardiance (Empagliflozin)

        3. Farxiga/Forxiga (Dapagliflozin)

        4. Suglat (Ipragliflozin)

      5. 5.1.5 DPP-4 inhibitors

        1. Onglyza (Saxagliptin)

        2. Tradjenta (Linagliptin)

        3. Vipidia/Nesina(Alogliptin)

        4. Galvus (Vildagliptin)

      6. 5.1.6 Sulfonylureas

        1. Sulfonylureas

      7. 5.1.7 Meglitinides

        1. Meglitinides

    2. 5.2 Insulins (Value and Volume, 2016-2027)

      1. 5.2.1 Basal or Long Acting Insulins

        1. Lantus (Insulin Glargine)

        2. Levemir (Insulin Detemir)

        3. Toujeo (Insulin Glargine)

        4. Tresiba (Insulin Degludec)

        5. Basaglar (Insulin Glargine)

      2. 5.2.2 Bolus or Fast Acting Insulins

        1. NovoRapid/Novolog (Insulin Aspart)

        2. Humalog (Insulin Lispro)

        3. Apidra (Insulin Glulisine)

      3. 5.2.3 Traditional Human Insulins

        1. Novolin/Actrapid/Insulatard

        2. Humulin

        3. Insuman

      4. 5.2.4 Biosimilar Insulins

        1. Insulin Glargine Biosimilars

        2. Human Insulin Biosimilars

    3. 5.3 Combination drugs (Value and Volume, 2016-2027)

      1. 5.3.1 Insulin combinations

        1. NovoMix (Biphasic Insulin Aspart)

        2. Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. Xultophy (Insulin Degludec and Liraglutide)

      2. 5.3.2 Oral Combinations

        1. Janumet (Sitagliptin and Metformin)

    4. 5.4 Non-Insulin Injectable drugs (Value and Volume, 2016-2027)

      1. 5.4.1 GLP-1 receptor agonists

        1. Victoza (Liraglutide)

        2. Byetta (Exenatide)

        3. Bydureon (Exenatide)

        4. Trulicity (Dulaglutide)

        5. Lyxumia (Lixisenatide)

      2. 5.4.2 Amylin Analogue

        1. Symlin (Pramlintide)


    1. 6.1 Type-1 Diabetic Population (2016-2027)

    2. 6.2 Type-2 Diabetic Population (2016-2027)



      1. 7.1.1 Takeda

      2. 7.1.2 Novo Nordisk

      3. 7.1.3 Pfizer

      4. 7.1.4 Eli Lilly

      5. 7.1.5 Janssen Pharmaceuticals

      6. 7.1.6 Astellas

      7. 7.1.7 Boehringer Ingelheim

      8. 7.1.8 Merck And Co.

      9. 7.1.9 AstraZeneca

      10. 7.1.10 Bristol Myers Squibb

      11. 7.1.11 Novartis

      12. 7.1.12 Sanofi


You can also purchase parts of this report. Do you want to check out a section wise price list?

Iran Diabetes Care Drugs Market Research FAQs

The Iran Diabetes Care Drugs Market is studied from 2018 - 2028.

The Iran Diabetes Care Drugs Market is growing at a CAGR of >4% over the next 5 years.

The Iran Diabetes Care Drugs Market is valued at 282 Million USD in 2018.

The Iran Diabetes Care Drugs Market is valued at 345 Million USD in 2028.

Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi, NovoNordisk are the major companies operating in Iran Diabetes Care Drugs Market.

Iran Diabetes Care Drugs Industry Report

Statistics for the 2023 Iran Diabetes Care Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Iran Diabetes Care Drugs analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!